Allogeneic vs autologous stem cells: a donor's cells, or your own
In mesenchymal stem cell (MSC) therapy, autologous means the cells are your own, harvested and returned to you, and allogeneic means they come from a donor, most commonly a consented mother contributing umbilical cord tissue after delivery. This page is about that therapy, and it leaves the stem cell transplants used for blood cancers to transplant medicine.
Two routes, and they play out very differently in practice.
Which one Celva usesMedically reviewed by the physician team at Hospital Angeles, October 2026
Which one does Celva use?
Every Celva cell is allogeneic.
This is the point patients most often get backwards, so it's worth stating plainly: Celva does not use your own cells. Every cell we infuse is allogeneic, donor-derived and manufactured ahead of time. Umbilical-cord MSCs for systemic work, and donor bone-marrow MSCs or chondrocytes at a target site when a case calls for it. None of it is harvested from your body.
The one thing some patients receive that does come from their own body is PRP, platelet-rich plasma, and it is not a stem cell product. PRP is a small concentrate of growth factors spun down from your own blood. It plays a limited, optional role as a local adjunct in select spine cases, never as a substitute for the cell therapy and never the main event. If you have read "autologous" elsewhere and assumed it meant your own stem cells, this is the distinction that matters: our cells are donor cells, start to finish.
What is the difference between autologous and allogeneic stem cells?
Autologous lives inside a single procedure room and a single day. Allogeneic lives across a donor screening, a cGMP facility, and a clinical-supply chain. The patient shows up only at the end.
Autologous harvest, then return
Autologous therapy uses the patient's own cells. Harvest, process, return to the same person. The cells are biologically identical to the patient (same DNA, same MHC markers), so rejection is not a concern.
-
Day 0
Patient arrives
Procedure begins under local anesthesia, sometimes with sedation.
-
Day 0
Harvest
Bone marrow aspirate or fat liposuction. Few MSCs, unexpanded.
-
Day 0
Minimal processing
Centrifuge / filter. No real expansion. No batch QC.
-
Day 0
Return same-day
Injected or infused back into the same patient.
- Total time:
- hours
- Sites touched:
- 1 clinic
- QC release:
- none
Allogeneic donor, then manufacture, then deliver
Allogeneic therapy uses cells from another person, a donor. The donor is typically rigorously screened. For mesenchymal stem cells, the donor is most commonly a consented mother contributing umbilical cord tissue after delivery.
-
Week 0
Consented donor
Screened mother donates cord tissue post-delivery. Pathogen panel.
-
Week 1 to 6
cGMP expansion
Isolated MSCs expanded over weeks. 100M+ per batch.
-
Week 6 to 7
Batch testing
Sterility, identity, viability, potency, endotoxin, mycoplasma. Released only after the 14-day sterility result.
-
Day of dose
Banked, then thawed
Thawed and re-checked the morning of treatment, viability re-confirmed post-thaw before the dose is drawn.
- Total time:
- weeks (about 4 to 8 per batch)
- Sites touched:
- donor, facility, clinic
- QC release:
- full panel
Your own cells and a donor's, property by property
Each row sets autologous and allogeneic side by side on one dimension that matters clinically. Autologous therapy isn't biologically inferior in every context. There are real reasons it's still around.
Cell age biological age of the donor Your own: Patient's age A donor's: Newborn (cord) Read moreShow less
Allogeneic cord cells are newborn cells. They've existed for nine months. Autologous cells are the patient's age. For older patients, this is a meaningful gap. Older cells have shorter telomeres, accumulated mutations, lower proliferative capacity, and weaker secretome (the cocktail of growth factors and signaling molecules MSCs release).
Yield per harvest cells produced per event Your own: Few MSCs A donor's: 100M+ MSCs Read moreShow less
A single cord can yield enough starting tissue to expand into hundreds of millions of cells across multiple batches. In a single bone marrow pull, well under 0.01% of the nucleated cells are MSCs. Allogeneic manufacturing produces large doses; autologous harvest produces small doses.
Patient procedure burden what the recipient undergoes Your own: Aspirate / lipo A donor's: No harvest Read moreShow less
The patient does not undergo a procedure to produce cells. No bone marrow aspirate. No liposuction. No anesthesia. No same-day surgical burden on a body that's already managing a chronic condition.
Cross-patient consistency standardization across recipients Your own: Variable Batch QC: none A donor's: Standardized Batch QC: full release panel Read moreShow less
Every patient receiving cells from the same allogeneic batch receives the same product: same characterization, same potency, same release testing. Autologous therapy is by definition variable: each patient is their own batch, with their own variable yield, viability, and potency.
Rejection risk immune incompatibility Your own: None by definition A donor's: Rare Read moreShow less
Autologous cells cannot trigger immune rejection. While allogeneic MSCs are largely immune-evasive, "largely" isn't "always." Rare transient immune responses to allogeneic infusions are documented in the literature. With autologous, this category of risk does not exist.
Why allogeneic MSCs don't need HLA matchingU.S. regulatory burden FDA pathway difficulty Your own: Exception for some A donor's: Requires IND Read moreShow less
The FDA's "same surgical procedure" exception covers minimally manipulated autologous tissue transferred during a single surgical encounter. Bone marrow concentrate prepared and given in one visit can fit it. Fat-derived SVF does not: the FDA treats it as a drug, and two federal appeals courts agreed (2021 and 2024). Allogeneic therapy in the U.S. requires an Investigational New Drug application, a path that takes years and costs millions.
Autologous cell therapy looks more like conventional clinical practice. The harvest is a procedure clinicians know how to perform. The processing is minimal. The product is the patient's own tissue. For regulators and clinicians, it sits in familiar territory.
Why allogeneic MSCs don't need HLA matching
Conventional allogeneic transplant (kidney, heart) triggers rejection because donor cells display surface markers that the recipient's immune system reads as foreign. MSCs largely don't show those markers, so the rejection cascade never starts.
Read moreShow less
In conventional medicine (kidney transplants, bone marrow transplants for leukemia), allogeneic transfers raise the immunology challenges patients have heard about: HLA matching, immunosuppressive medication, graft-versus-host disease. But mesenchymal stem cells are biologically different. They are immune-evasive, not invisible: they express low levels of MHC class I, little or no MHC class II unless stimulated, and lack co-stimulatory molecules, which is why they don't trigger the conventional rejection cascade. This is why allogeneic MSC therapy can be administered without HLA matching and without immunosuppression. It is a different biology than allogeneic organ transplantation.
A typical somatic cell Visible to the immune system.
Full MHC display + co-stimulatory ligands. Donor to recipient = rejection cascade.
- MHC-IPresent
- MHC-IIPresent
- CD80/86Present
- NetRejected
A mesenchymal stem cell Hard to see, not invisible.
Low MHC-I, no MHC-II at rest, no co-stimulation. Donor to recipient = tolerated in most cases.
- MHC-ILow
- MHC-IIAbsent at rest
- CD80/86Absent
- NetTolerated
Conventional transplant HLA matching required. Plus chronic immunosuppression. Plus the possibility of acute or chronic graft rejection.
Allogeneic MSC infusion No HLA matching. No immunosuppression. Routine IV delivery without the rejection cascade conventional transplants raise.
Where allogeneic MSC therapy is authorized
The published evidence base for mesenchymal stem cell therapy spans hundreds of clinical trials. The largest body of trials uses allogeneic cells, typically umbilical cord-derived, for indications ranging from osteoarthritis to graft-versus-host disease to autoimmune conditions to wound healing.
Allogeneic MSC products have received conditional or full marketing authorization in several jurisdictions outside the U.S. The FDA has approved one allogeneic MSC product: Ryoncil, for steroid-refractory acute graft-versus-host disease in pediatric patients. The autologous evidence base is also substantial, but more concentrated in orthopedics and harvest-based research protocols.
Approvals are geographic.
United States Allogeneic = drug. Autologous = it depends on the processing.
- USA, allogeneicRyoncil (remestemcel-L) pediatric GvHDApproved
- USA, allogeneicAll other allogeneic MSC therapiesIND only
- USA, autologousSame-surgical-procedure tissue (BMAC)Exception
- USA, autologousFat-derived SVFDrug
Outside the United States Multiple authorized allogeneic products.
- KORCartistem osteoarthritis (cord blood)Approved
- JPNTemcell GvHD (bone marrow)Approved
- INDStempeucel critical limb ischemia (bone marrow)Approved
How to read a clinic's source claims
When you're sizing up a clinic, the words it uses for its source tell you a lot. Some patterns:
Stem cells
Imprecise, evasive
Source not named. Either marketing imprecision or actively avoiding the question. A serious program names the tissue, the modality, and the manufacturer.
Ask Which source: cord, marrow, fat? Allogeneic or autologous?
Your own cells
Autologous, U.S.
Usually an autologous-only program operating in the U.S. under the same-surgical-procedure framework. May be the right tool, particularly for orthopedic point-of-care. Not the same therapy as cord-derived allogeneic.
Ask What dose, what processing, what characterization is delivered?
Umbilical cord stem cells
Allogeneic, cord
Allogeneic, cord-derived. Often Wharton's jelly MSCs expanded in a cGMP facility.
Ask Donor screening? Facility? Batch testing? Cell count?
SVF or stromal vascular fraction
Autologous, adipose
Adipose-derived autologous, minimally manipulated. Usually same-day harvest-and-inject. The yield and viability vary by harvest, by patient, by clinic.
Ask Cell count delivered? Viability? Variability across procedures?
Exosomes, growth factors, stem cell secretions
Not stem cells
Different category. These are cell-derived products, not living cells. Different evidence base, different mechanism, different regulatory framing.
Ask What is actually in the vial? See the glossary.
A combination of multiple sources
Mixed, clarify
Sometimes legitimate (for example, allogeneic cord MSCs systemically plus allogeneic bone-marrow MSCs or chondrocytes at the target site). Sometimes vague language hiding a thin product. Press for specifics.
Ask What goes in the body, in what dose, in what order?
Donor cord cells rank first. Your own cells are a different tool.
For some applications, particularly orthopedic point-of-care injections, autologous bone marrow concentrate has a real evidence base. The question isn't "is autologous valid": it's "is autologous the right tool for this condition, at this dose, in this patient?"
Your own cells
Strong fit when the indication is orthopedic, point-of-care, and the patient is healthy enough to tolerate a harvest procedure.
Donor cells
Strong fit for systemic, chronic, immunomodulatory indications where dose, age, and standardization matter.
Real programs name the source.
A clinic that says "stem cells" without saying allogeneic or autologous, and without naming the source tissue, has decided not to tell you. Press for the answer.